RTW's Rod Wong defends China in-licensing, argues it grows the US biotech pie, and responds to critics of the Serapha Bio launch.
Last week, I sat down with Rod Wong, RTW Investments’ chief investment officer, at his firm’s office overlooking NYC’s Little Island, as New York Knicks’ …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Bigger, fewer, tougher: the new era of China-US biotech partnerships
The U.S.-China biotech crackdown may hurt the scientists America needs the most
Hong Kong draws royalties giant as mainland China biotech licensing heats up
The China debate gets louder in Washington
At BIO, tension over China biotech deal regulation looms
Opinion | Hong Kong can take the regulatory high road amid US-China AI decoupling
HHS, responding to China’s rise, moves to fast-track early drug research
BIO makes China political strategy a top priority as US weighs outbound investment limits; CEO Crowley says biotech may fall…
The veteran investor says that the trove of ready-made prospects is making the global biotech ecosystem “more competitive” and…
China’s biotech boom continues to attract Western drug makers even as Washington expands investment and technology controls.
PhRMA and BIO mobilize against a wave of anti-China biotech bills in Congress as lawmakers move to curb US dealmaking with China.
“There is a difference between a policy based on evidence and a broad legislative response that targets China-origin entities as…
Two federal lawmakers have introduced a bill seeking to apply the review requi | Two federal lawmakers have introduced a bill…
